|
|
| Liu,Lun-Fei; Chen,Ji-Su; Shen,Ji-Yang; Dou,Ting-Ting; Zhou,Jiong; Cai,Sui-Qing; Zheng,Min. |
| Psoriasis is a T-cell mediated disease that involves IL-23/Th17 and IL-12/Th1 axes. Ustekinumab, a fully human monoclonal antibody targeting the p40 subunit of both IL-12 and IL-23, has proven to be efficient and safe for treating patients with psoriasis. Yet, there have been no reports with human skin/blood samples that would elucidate the molecular mechanisms by which ustekinumab calms psoriasis skin lesions. To investigate the efficacy and molecular pathway (RORC, t-BOX and GATA) of ustekinumab in treating patients with psoriasis skin lesions. A total of 30 patients with psoriasis were randomized into placebo group and treatment group. PASI of each patient was calculated at 0, 12 and 24 weeks post-treatment. The mRNA levels of RORC, t-BOX and GATA in... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Psoriasis; Ustekinumab/efficacy; Biologic agents. |
| Ano: 2018 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502018000400615 |
| |
